Innovation will pull Coloplast up to the high end of growth expectations, says CEO Kristian Villumsen, who predicts that the growth engines could accelerate based on new products introduced in the market, according to Danish financial daily Børsen.

Coloplast’s billion-dollar acquisitions of Atos Medical and Kerecis have grown by 10% and 35% respectively, which is above the strategic target of 8-10% growth that has been in place at Coloplast for a number of years.

”The reason we have the long-term target that we have is that there is always a bit of put and take. But make no mistake - the ambition is to accelerate the company,” says Villumsen and continues:

”The ambition is of course to get as close to the high end of that range as possible. And if we feel there’s a possibility that we can beat that, we’ll let the market know,” he says.

Villumsen believes that Kerecis’ fish skin product, which is being developed for wound care products, has the potential to become the market leader in biological wound care products in the US, which requires a market share of 25-30% compared to the current share of less than 5%.

English edit: Catherine Brett